Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Emmerich

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Journal of Leukocyte Biology|July 9, 2002
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODNB Jahrsdörfer, R Jox, L Mühlenhoff, et al.
Oncology|March 5, 2011
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and SwitzerlandI Hrusovsky, B Emmerich, A von Rohr, et al.
Blood|June 1, 1997
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemiaW U Knauf, B Ehlers, B Mohr, et al.
Leukemia & Lymphoma|March 18, 2000
Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemiaB Gahn, G Brittinger, G Dölken, et al.
Seminars in Oncology|December 1, 1994
Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomasH H Gerhartz, M Engelhard, G Brittinger, et al.
Gastroenterology Report|February 21, 2025
Micro-environmental changes indicate potential for subclinical intestinal tissue damage in early-age-onset colorectal cancer patientsSean G Kraus, Katherine A Johnson, Philip B Emmerich, et al.
British Journal of Haematology|July 1, 1996
Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cellsM Hallek, S Danhauser-Riedl, R Herbst, et al.
Blood|February 25, 1999
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemiaM Hallek, I Langenmayer, C Nerl, et al.
Current Treatment Options in Oncology|April 25, 2020
Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment SelectionKatherine A Johnson, Rebecca A DeStefanis, Philip B Emmerich, et al.
Leukemia & Lymphoma|February 26, 1998
Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemiaW U Knauf, I Langenmayer, B Ehlers, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Journal of Leukocyte Biology|July 9, 2002
Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODNB Jahrsdörfer, R Jox, L Mühlenhoff, et al.
Oncology|March 5, 2011
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and SwitzerlandI Hrusovsky, B Emmerich, A von Rohr, et al.
Blood|June 1, 1997
Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemiaW U Knauf, B Ehlers, B Mohr, et al.
Leukemia & Lymphoma|March 18, 2000
Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemiaB Gahn, G Brittinger, G Dölken, et al.
Seminars in Oncology|December 1, 1994
Recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to chemotherapy in aggressive non-Hodgkin's lymphomasH H Gerhartz, M Engelhard, G Brittinger, et al.
Gastroenterology Report|February 21, 2025
Micro-environmental changes indicate potential for subclinical intestinal tissue damage in early-age-onset colorectal cancer patientsSean G Kraus, Katherine A Johnson, Philip B Emmerich, et al.
British Journal of Haematology|July 1, 1996
Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cellsM Hallek, S Danhauser-Riedl, R Herbst, et al.
Blood|February 25, 1999
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemiaM Hallek, I Langenmayer, C Nerl, et al.
Current Treatment Options in Oncology|April 25, 2020
Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment SelectionKatherine A Johnson, Rebecca A DeStefanis, Philip B Emmerich, et al.
Leukemia & Lymphoma|February 26, 1998
Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemiaW U Knauf, I Langenmayer, B Ehlers, et al.
Pageof 15